SS
LGND icon

SBI Securities’s Ligand Pharmaceuticals LGND Stock Holding History

SBI Securities’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.5K Buy
106
+105
+10,500% +$24.7K ﹤0.01% 1325
2026
Q1 		$200 Hold
1
– – ﹤0.01% 3217
2025
Q4 		$189 Hold
1
– – ﹤0.01% 3230
2025
Q3 		$177 Sell
1
-1
-50% -$149 ﹤0.01% 3356
2025
Q2 		$227 Buy
2
+1
+100% +$107 ﹤0.01% 3268
2025
Q1 		$105 Buy
+1
New +$113 ﹤0.01% 3427

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SBI Securities's LGND Position: Q2 2026 in Review

SBI Securities increased its Ligand Pharmaceuticals (LGND) stake by 10,500% in Q2 2026, buying an estimated $24.7K and bringing the position to 106 shares worth $33.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1325.

SBI Securities first reported a position in LGND in Q1 2025 and has held it in 6 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • SBI Securities held 106 shares of Ligand Pharmaceuticals worth $33.5K as of Q2 2026.
  • SBI Securities bought 105 Ligand Pharmaceuticals shares in Q2 2026, an estimated $24.7K.
  • Ligand Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #1325 holding.
  • SBI Securities first reported a position in Ligand Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.